You just read:

First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Aug 01, 2018, 03:00 ET